showing 3 related works from this author
Prolonged-release buprenorphine formulations: Perspectives for clinical practice
2020
International audience; Buprenorphine and methadone are the two main opioid agonist treatments approved for opioid use disorder. Buprenorphine is a partial agonist of the mu opioid receptors, which has been merely available through sublingual form until now. In practice, the use of buprenorphine is smoother than that of methadone, and it induces reduced risks of overdose. However, sublingual buprenorphine also exposes to risks (e.g., withdrawal, misuse) and constraints (e.g., daily intake). Three new galenic formulations of prolonged-release buprenorphine (PRB) are being commercialized and should allow some improvements in patients' comfort and safety. This narrative review aims to describe…
Buprénorphine d’action prolongée : quelles perspectives pour la pratique clinique ?
2020
Resume La buprenorphine et la methadone sont les deux traitements agonistes opioides indiques dans le trouble de l’usage des opiaces et opioides. La buprenorphine est un agoniste partiel des recepteurs opioides mu, jusqu’a present disponible exclusivement en administration sublinguale. En pratique, la buprenorphine est plus sure que la methadone, car elle induit un faible risque de surdosage. Cependant, la buprenorphine expose egalement a des risques (par exemple : syndromes de sevrage ou mesusages) et a des contraintes (prise quotidienne, souvent longue dissolution sublinguale). Trois nouvelles formulations galeniques de buprenorphine d’action prolongee (BAP) sont en cours de commercialisa…
Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone
2021
International audience; Aim: To explore the factors determining the interest in extended-release buprenorphine (XR-BUP) injections among patients receiving opioid agonist treatment (OAT) in France.Methods: 366 patients receiving OAT for opioid use disorder, recruited in 66 French centers, were interviewed from 12/2018 to 05/2019. A structured questionnaire assessed their interest in XR-BUP using a [1-10] Likert scale. 'More' vs. 'less' interested groups were defined using the median score of interest, and their characteristics were explored using adjusted odds ratios (aORs) and 95 % confidence interval (95 %CI). Independent variables were as follows: sociodemographic characteristics, OAT-re…